Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
life sciences
national blog main
san francisco blog main
5
×
boston blog main
boston top stories
boston
cancer
cancer drugs
deals
fda
investing
national top stories
new york blog main
rare disease drugs
san francisco top stories
acute migrane
akouos
amgen
astellas pharma
astellas pharmaceuticals
atlas venture
audentes therapeutics
avidity biosciences
bain capital
bausch health
black diamond therapeutics
bladder cancer
bluebird bio
blueprint medicines
breast cancer
california institute for biomedical research
cobimetinib
decibel therapeutics
deciphera pharmaceuticals
desmoid tumor
dihydroergotamine
dihydroergotamine mesylate
duchenne muscular dystrophy
What
drug
5
×
ipo
5
×
medicines
therapeutics
biotech
cancer
companies
ipos
leading
research
targets
activity
affects
ago
americans
approved
biotechs
black
clinic
considering
data
date
days
despite
developing
diamond
diseases
dog
dyne
early
eluded
expected
experimental
eyes
family
fda
firm
frequency
genetic
hardest
Language
unset
5
×
Current search:
drug
×
unset
×
" san francisco blog main "
×
ipo
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs